Related Experiment Videos
Antiplatelets match anticoagulants for VTE prevention after joint arthroplasty: a meta-analysis of randomized
Liwei Zhang1, Hua Luo1, Yuhang Gong1
1Department of Orthopedics, Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University, Taizhou, Zhejiang, China.
Purpose:
Venous thromboembolism (VTE), encompassing deep vein thrombosis (DVT) and pulmonary embolism (PE), remains a major risk after joint arthroplasty. This study compares antiplatelet agents versus anticoagulants for VTE prevention in adults undergoing joint arthroplasty.
Methods:
The review process was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Systematic searches were conducted in PubMed, EMBASE, Web of Science, and the Cochrane Central Register of Controlled Trials. Randomized controlled trials (RCTs) comparing antiplatelets with anticoagulants for VTE prevention in adults undergoing joint arthroplasty were included. Data were pooled using a random effects meta-analysis to account for heterogeneity.
Results:
Nineteen RCTs involving 30,290 patients met the inclusion criteria. No significant difference was found between antiplatelet agents and anticoagulants in preventing VTE (risk ratio (RR): 1.08; 95% CI: 0.81-1.44), DVT (RR: 1.12; 95% CI: 0.83-1.51), or PE (RR: 1.26; 95% CI: 0.94-1.69). However, in studies conducted after 2015 and those incorporating mechanical prophylaxis, the antiplatelet group had higher rates of VTE, DVT, and PE. Notably, female patients on antiplatelets had lower VTE rates, suggesting potential sex-specific benefits. Regarding safety, antiplatelet agents were associated with fewer bleeding complications compared to anticoagulants.
Conclusion:
Antiplatelet agents are as effective as anticoagulants in preventing VTE, DVT, and PE after joint arthroplasty and may offer a better safety profile with fewer bleeding complications. Despite some heterogeneity and potential biases, the evidence supports considering antiplatelet agents, particularly aspirin, as a cost-effective and reliable option for VTE prophylaxis in this patient population.
Related Concept Videos
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Formation of the Platelet Plug
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Coronary Artery Disease V: Interprofessional Care